174 related articles for article (PubMed ID: 34081254)
41. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance.
Bourguignon LYW; Earle C; Shiina M
Matrix Biol; 2019 May; 78-79():180-200. PubMed ID: 30077625
[TBL] [Abstract][Full Text] [Related]
42. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin.
Matou-Nasri S; Gaffney J; Kumar S; Slevin M
Int J Oncol; 2009 Oct; 35(4):761-73. PubMed ID: 19724912
[TBL] [Abstract][Full Text] [Related]
43. Low molecular weight hyaluronan mediated CD44 dependent induction of IL-6 and chemokines in human dermal fibroblasts potentiates innate immune response.
Vistejnova L; Safrankova B; Nesporova K; Slavkovsky R; Hermannova M; Hosek P; Velebny V; Kubala L
Cytokine; 2014 Dec; 70(2):97-103. PubMed ID: 25126764
[TBL] [Abstract][Full Text] [Related]
44. Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.
Song JM; Molla K; Anandharaj A; Cornax I; O Sullivan MG; Kirtane AR; Panyam J; Kassie F
Oncotarget; 2017 Apr; 8(16):26927-26940. PubMed ID: 28460475
[TBL] [Abstract][Full Text] [Related]
45. A novel role of low molecular weight hyaluronan in breast cancer metastasis.
Wu M; Cao M; He Y; Liu Y; Yang C; Du Y; Wang W; Gao F
FASEB J; 2015 Apr; 29(4):1290-8. PubMed ID: 25550464
[TBL] [Abstract][Full Text] [Related]
46. Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
Park GB; Ko HS; Kim D
Mol Med Rep; 2017 Aug; 16(2):1826-1836. PubMed ID: 28627617
[TBL] [Abstract][Full Text] [Related]
47. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer.
Udabage L; Brownlee GR; Nilsson SK; Brown TJ
Exp Cell Res; 2005 Oct; 310(1):205-17. PubMed ID: 16125700
[TBL] [Abstract][Full Text] [Related]
48. Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
Gutjahr JC; Szenes E; Tschech L; Asslaber D; Schlederer M; Roos S; Yu X; Girbl T; Sternberg C; Egle A; Aberger F; Alon R; Kenner L; Greil R; Orian-Rousseau V; Hartmann TN
Blood; 2018 Mar; 131(12):1337-1349. PubMed ID: 29352038
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy.
Aaltomaa S; Lipponen P; Viitanen J; Kankkunen JP; Ala-Opas M; Kosma VM
Eur Urol; 2000 Nov; 38(5):555-62. PubMed ID: 11096236
[TBL] [Abstract][Full Text] [Related]
50. Distinct kinetic and molecular requirements govern CD44 binding to hyaluronan versus fibrin(ogen).
Raman PS; Alves CS; Wirtz D; Konstantopoulos K
Biophys J; 2012 Aug; 103(3):415-423. PubMed ID: 22947857
[TBL] [Abstract][Full Text] [Related]
51. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.
Birzele F; Voss E; Nopora A; Honold K; Heil F; Lohmann S; Verheul H; Le Tourneau C; Delord JP; van Herpen C; Mahalingam D; Coveler AL; Meresse V; Weigand S; Runza V; Cannarile M
Clin Cancer Res; 2015 Jun; 21(12):2753-62. PubMed ID: 25762343
[TBL] [Abstract][Full Text] [Related]
52. Hyaluronic acid binding to CD44S is indiscriminate of molecular weight.
Kim SJ; Owen SC
Biochim Biophys Acta Biomembr; 2020 Sep; 1862(9):183348. PubMed ID: 32428448
[TBL] [Abstract][Full Text] [Related]
53. High molecular weight form of hyaluronic acid reduces neuroinflammatory response in injured sciatic nerve via the intracellular domain of CD44.
Jou IM; Wu TT; Hsu CC; Yang CC; Huang JS; Tu YK; Lee JS; Su FC; Kuo YL
J Biomed Mater Res B Appl Biomater; 2021 May; 109(5):673-680. PubMed ID: 32924257
[TBL] [Abstract][Full Text] [Related]
54. Effect of CD44 suppression by antisense oligonucleotide on attachment of human trabecular meshwork cells to HA.
Li Z; Zhang H
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(5):486-9. PubMed ID: 15641700
[TBL] [Abstract][Full Text] [Related]
55. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
56. Hyaluronic acid, CD44 and RHAMM regulate myoblast behavior during embryogenesis.
Leng Y; Abdullah A; Wendt MK; Calve S
Matrix Biol; 2019 May; 78-79():236-254. PubMed ID: 30130585
[TBL] [Abstract][Full Text] [Related]
57. CD44 and hyaluronic acid regulate in vivo iNOS expression and metalloproteinase activity in murine air-pouch inflammation.
Cabrera PV; Blanco G; Alaniz L; Greczanik S; Garcia M; Alvarez E; Hajos SE
Inflamm Res; 2004 Oct; 53(10):556-66. PubMed ID: 15597151
[TBL] [Abstract][Full Text] [Related]
58. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
[TBL] [Abstract][Full Text] [Related]
59. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth.
Bourguignon LY; Zhu H; Zhou B; Diedrich F; Singleton PA; Hung MC
J Biol Chem; 2001 Dec; 276(52):48679-92. PubMed ID: 11606575
[TBL] [Abstract][Full Text] [Related]
60. CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2.
Kim Y; Lee YS; Choe J; Lee H; Kim YM; Jeoung D
J Biol Chem; 2008 Aug; 283(33):22513-28. PubMed ID: 18577517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
